One member asked what cash-pay practices are doing about compounded tirzepatide and semaglutide now that the FDA is cracking down. The answers were practical.
Branded manufacturer programs such as Lilly Direct and Novo Direct are viable alternatives to compounding, but they get expensive at higher doses, where compounded tirzepatide can still be cost-competitive.
Oral semaglutide produces less weight loss than the injectable, requires daily dosing and still causes nausea. Members still see a role for it in glucose control and for some inflammatory and anxiety benefits.
The Lilly Direct Qwikpen has a one-year beyond-use date, so patients can stock up, but they must order at least every 45 days to keep the discounted price. Lilly also offers expanded access to branded retatrutide at no cost for qualifying patients, with significant paperwork. And compounders have raised prices to match branded competition, narrowing the gap at higher doses.
Key takeaways
- Branded direct programs work, but price rises steeply with dose.
- Oral semaglutide is weaker for weight loss but has other uses.
- Watch the Qwikpen ordering window and the retatrutide expanded-access route.
- The price gap with compounders is shrinking.
From Buzz in the chat, the longevitydocs™ Sunday newsletter, September 6, 2026. Member discussion, not clinical guidance.
Originally published in The Longevity Medicine Intelligence newsletter.
